HER2-low expression, currently defined as an IHC score of 1+ or 2+ with no amplification of the HER2 gene when analyzed via ISH assay [4,5], has currently resulted in tumors being classified as luminal-like or triple-negative breast cancers. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.